Piper Sandler Maintains Neutral on 10x Genomics, Raises Price Target to $47

10x Genomics

10x Genomics

TXG

0.00

Piper Sandler analyst David Westenberg maintains 10x Genomics (NASDAQ: TXG) with a Neutral and raises the price target from $42 to $47.